Clinical Trials Logo

Filter by:
NCT ID: NCT00413218 Completed - Mycoses Clinical Trials

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Start date: March 8, 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

NCT ID: NCT00412984 Completed - Atrial Fibrillation Clinical Trials

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

ARISTOTLE
Start date: December 31, 2006
Phase: Phase 3
Study type: Interventional

The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

NCT ID: NCT00412893 Completed - Aspergillosis Clinical Trials

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Start date: March 7, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.

NCT ID: NCT00412698 Terminated - Obesity Clinical Trials

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

ETERNAL
Start date: December 2006
Phase: Phase 3
Study type: Interventional

Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with dyslipidemia with or without other associated comorbidities. Main Secondary : To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic and lipid parameters. To assess the safety of 12 months Rimonabant treatment versus placebo in these patients. In selected sites, a sub study will be conducted to determine the effect of 12 months of Rimonabant on additional lipoprotein and inflammatory parameters.

NCT ID: NCT00412685 Completed - Tetralogy of Fallot Clinical Trials

Myocardial Contrast Echocardiography in Congenital Heart Disease

Start date: August 2006
Phase: N/A
Study type: Observational

Patients with congenital heart disease in whom the right ventricle is exposed to pressure or volume overload show progressive systolic dysfunction of the right ventricle, the fact of which conveys substantial morbidity and mortality. The aim of this study is to investigate the myocardial perfusion in these patients by myocardial contrast echocardiography (MCE) in order to determine whether disturbed blood flow plays a role in the development of right ventricular systolic dysfunction.

NCT ID: NCT00410761 Active, not recruiting - Thyroid Cancer Clinical Trials

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Start date: November 30, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

NCT ID: NCT00410631 Recruiting - Neuroblastoma Clinical Trials

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Start date: October 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. An autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether observation is more effective than combination chemotherapy, radiation therapy, and/or autologous stem cell transplant in treating neuroblastoma. PURPOSE: This randomized phase III and phase IV trial is studying observation, combination chemotherapy, radiation therapy, and/or autologous stem cell transplant to compare how well they work in treating young patients with neuroblastoma.

NCT ID: NCT00410410 Completed - Ulcerative Colitis Clinical Trials

A Study of Abatacept in Patients With Active Ulcerative Colitis

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied

NCT ID: NCT00410228 Completed - Healthy Clinical Trials

Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of ascending single oral doses of AHT956 in healthy subjects

NCT ID: NCT00410111 Completed - Sepsis Clinical Trials

Pathogenesis and Cerebrovascular Manifestations of Septic Encephalopathy

Start date: January 2007
Phase: N/A
Study type: Observational

Septic encephalopathy is an important complication of sepsis. Why some patients with sepsis develop septic encephalopathy is unknown. We will investigate whether patients who develop this condition have different patterns of cerebrovascular reactivity and whether it is possible to predict the development of septic encephalopathy from early measurements of cerebral perfusion or from the EEG. We will specifically test the hypotheses that septic encephalopathy may not be predicted by changes in the EEG, and that cerebrovascular autoregulation is not dysfunctional in septic encephalopathy.